Cargando…
ASCO 2016 – update colorectal liver metastases
This short review summarizes the most relevant data on colorectal liver metastases (CLM) presented at the 2016 Annual Meeting of the American Society of Clinical Oncology (ASCO). For this update, congress abstracts were grouped into three clinically relevant scenarios: CLM that are deemed upfront re...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Vienna
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5493718/ https://www.ncbi.nlm.nih.gov/pubmed/28725278 http://dx.doi.org/10.1007/s12254-016-0308-y |
_version_ | 1783247551754928128 |
---|---|
author | Kaczirek, Klaus |
author_facet | Kaczirek, Klaus |
author_sort | Kaczirek, Klaus |
collection | PubMed |
description | This short review summarizes the most relevant data on colorectal liver metastases (CLM) presented at the 2016 Annual Meeting of the American Society of Clinical Oncology (ASCO). For this update, congress abstracts were grouped into three clinically relevant scenarios: CLM that are deemed upfront resectable, borderline resectable, and primarily unresectable. According to a large registry study, small, upfront resectable, solitary CLM should be resected using a parenchymal sparing technique. A prospective noninterventional study suggested that chemotherapy plus the anti-VEGF (vascular endothelial growth factor) antibody bevacizumab is effective and well tolerated in patients with borderline resectable CLM. In the setting of CLM deemed initially unresectable, a phase 2 study reported superior outcomes in terms of liver metastases resection rates as well as overall survival (OS) in patients receiving a chemotherapy triplet (FOLFIRINOX) plus a targeted agent as compared to FOLFIRI or FOLFOX4 with the same targeted therapy. Finally, a study suggested that tailoring first-line chemotherapy according to TYMS-3’UTR and ERCC1-118 polymorphism status results in higher response rates and longer progression-free survival (PFS) as well as OS. |
format | Online Article Text |
id | pubmed-5493718 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Springer Vienna |
record_format | MEDLINE/PubMed |
spelling | pubmed-54937182017-07-17 ASCO 2016 – update colorectal liver metastases Kaczirek, Klaus Memo Short Review This short review summarizes the most relevant data on colorectal liver metastases (CLM) presented at the 2016 Annual Meeting of the American Society of Clinical Oncology (ASCO). For this update, congress abstracts were grouped into three clinically relevant scenarios: CLM that are deemed upfront resectable, borderline resectable, and primarily unresectable. According to a large registry study, small, upfront resectable, solitary CLM should be resected using a parenchymal sparing technique. A prospective noninterventional study suggested that chemotherapy plus the anti-VEGF (vascular endothelial growth factor) antibody bevacizumab is effective and well tolerated in patients with borderline resectable CLM. In the setting of CLM deemed initially unresectable, a phase 2 study reported superior outcomes in terms of liver metastases resection rates as well as overall survival (OS) in patients receiving a chemotherapy triplet (FOLFIRINOX) plus a targeted agent as compared to FOLFIRI or FOLFOX4 with the same targeted therapy. Finally, a study suggested that tailoring first-line chemotherapy according to TYMS-3’UTR and ERCC1-118 polymorphism status results in higher response rates and longer progression-free survival (PFS) as well as OS. Springer Vienna 2017-01-17 2017 /pmc/articles/PMC5493718/ /pubmed/28725278 http://dx.doi.org/10.1007/s12254-016-0308-y Text en © The Author(s) 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
spellingShingle | Short Review Kaczirek, Klaus ASCO 2016 – update colorectal liver metastases |
title | ASCO 2016 – update colorectal liver metastases |
title_full | ASCO 2016 – update colorectal liver metastases |
title_fullStr | ASCO 2016 – update colorectal liver metastases |
title_full_unstemmed | ASCO 2016 – update colorectal liver metastases |
title_short | ASCO 2016 – update colorectal liver metastases |
title_sort | asco 2016 – update colorectal liver metastases |
topic | Short Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5493718/ https://www.ncbi.nlm.nih.gov/pubmed/28725278 http://dx.doi.org/10.1007/s12254-016-0308-y |
work_keys_str_mv | AT kaczirekklaus asco2016updatecolorectallivermetastases |